FDA-cleared blood tests for Alzheimer’s disease represent a major advance in how the condition can be detected and evaluated. These tests measure specific biomarkers in the blood—such as phosphorylated tau (p-tau) and beta-amyloid proteins—that are associated with the hallmark brain changes seen in Alzheimer’s. Because they require only a standard blood draw, they are far less invasive and more accessible than traditional diagnostic tools like PET scans or spinal taps, which have historically limited early detection.
These tests, which included Elecsys pTau181 and Lumipulse, are intended for adults, typically age 55 and older, who are already experiencing symptoms of cognitive decline, such as memory loss or confusion. They are not designed to diagnose Alzheimer’s on their own but are used alongside clinical assessments, cognitive testing, and imaging when needed. By helping clinicians determine whether Alzheimer’s-related pathology is likely present, blood tests can guide decisions about further evaluation, specialist referrals, and eligibility for emerging treatments that target amyloid in the brain.
The benefits of FDA-cleared Alzheimer’s blood tests include earlier detection, improved access to evaluation in primary care settings, and reduced costs compared with imaging. Earlier insight into the underlying cause of cognitive symptoms allows patients and families to plan for the future, consider treatment options sooner, and adopt lifestyle changes that may help slow progression. These tests also support more efficient use of advanced diagnostics by identifying who is most likely to benefit from additional testing.
However, there are important limitations to understand. No blood test can definitively diagnose Alzheimer’s disease, and false positives or false negatives are possible. Results must be interpreted within the broader clinical picture, including medical history and neurological evaluation. In addition, these tests are not approved for screening people without symptoms, and receiving biomarker information can carry emotional and psychological implications. As research advances, blood-based testing is expected to play an increasingly important role in earlier and more equitable Alzheimer’s care.
To learn more about these FDA-cleared tests, from AARP, CLICK HERE.
